Medicines for Europe calls on lawmakers not to increase fees

Medicines for Europe, the trade body for generics and biosimilars companies in the region, has called for “a fair, cost-based approach” to regulatory fees.

The group is arguing for a simpler fee structure, as well as adequate financing and “transparent evaluation of costs,” during the regulatory process for medicines.

Stressing the increased significance of regulatory fees for medicines which attract a lower price, Medicine for Europe said this approach would help avoid the withdrawal of older medicines from national markets, which may be essential for healthcare needs.